Microdosed midazolam for the determination of cytochrome P450 3A activity: Development and clinical evaluation of a buccal film

Kiene, Klara and Hayasi, Noriyuki and Burhenne, Jürgen and Uchitomi, Ryo and Sünderhauf, Claudia and Schmid, Yasmin and Haschke, Manuel and Haefeli, Walter Emil and Krähenbühl, Stephan and Mikus, Gerd and Inada, Hirohiko and Huwyler, Jörg. (2019) Microdosed midazolam for the determination of cytochrome P450 3A activity: Development and clinical evaluation of a buccal film. European Journal of Pharmaceutical Sciences, 135. pp. 77-82.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/71550/

Downloads: Statistics Overview


Cytochrome P450 3A (CYP3A) isozymes metabolize about 50% of all marketed drugs. Their activity can be modulated up to 400-fold, which has great impact on individual dose requirements for CYP3A substrates. The activity of CYP3A can be monitored using the CYP3A substrate midazolam. To avoid pharmacological midazolam effects during phenotyping, a microdosing approach is preferred. However, the preparation of microdosed dosage forms remains a challenge. Fast dissolving buccal films are therefore proposed to facilitate this task. It was the aim of the present study to clinically evaluate a novel buccal film containing microdoses of midazolam for assessment of CYP3A activity. In a randomized, open-label crossover design, the pharmacokinetics of midazolam and its active hydroxy-metabolite, 1'‑OH‑midazolam, was assessed in 12 healthy volunteers after administration of single microdoses of midazolam (30 μg) as buccal film or buccal solution. The buccal film did rapidly disintegrate, was well tolerated, and no adverse events occurred. The film and the solution showed very similar midazolam plasma concentration-time profiles but were not bioequivalent according to EMA and FDA guidelines. For C; max; , AUC; 0-12h; , and AUC; 0-∞; the geometric mean ratios of film to solution, with their 90% confidence intervals in parentheses, were 1.15 (1.00-1.32), 1.16 (1.04-1.28), and 1.19 (1.08-1.31), respectively. As a proxy for CYP3A activity, molar metabolic ratios of midazolam and 1'‑OH‑midazolam were analyzed over time, which revealed good correlations already 1 h or 2 h after application of the film or the solution, respectively. The tested midazolam buccal film is a convenient dosage form that facilitates administration of a phenotyping probe considerably and may potentially be used in special patient populations such as pediatric patients. Clinical Trials.gov Identifier: NCT03204578.
Faculties and Departments:05 Faculty of Science > Departement Pharmazeutische Wissenschaften > Pharmazie > Pharmaceutical Technology (Huwyler)
UniBasel Contributors:Huwyler, Jörg and Kiene, Klara
Item Type:Article, refereed
Article Subtype:Research Article
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:17 Aug 2020 15:02
Deposited On:17 Aug 2020 15:02

Repository Staff Only: item control page